What Happened
Three obesity-drug developers presented human trial data on amylin-based weight-loss candidates at the European Association for the Study of Diabetes congress in Milan, the most concentrated industry push yet toward the pancreatic hormone that controls post-meal fullness.
The candidates are splitting into two tiers. Injectable combinations that attach an amylin analogue to an incretin drug have posted the largest weight-loss figures recorded in obesity trials to date, while standalone amylin shots have delivered more moderate results with side-effect rates approaching placebo.
- CagriSema (Novo Nordisk) pairs the amylin analogue cagrilintide with semaglutide in one weekly injection. It is the amylin compound closest to market: the developer has filed with the U.S. Food and Drug Administration for adults with obesity or overweight but without diabetes, with a decision expected by the end of the year. Trial participants lost an average of 22.4% of starting body weight over roughly a year.
- EloraTZP (Eli Lilly) combines the amylin analogue eloralintide with tirzepatide. In adults with excess weight and type 2 diabetes, the pairing cut 23% of starting body weight over nearly a year, against 14.8% for tirzepatide alone. Additional studies are planned; no regulatory filing has been made.
- Petrelintide (Zealand Pharma) is a standalone weekly amylin injection with no GLP-1 component. Results published September 29 in The Lancet showed roughly 10% average weight loss in adults with overweight or obesity, against 1.7% for placebo — but the headline finding was tolerability, with adverse-event rates at the highest doses close to those of the placebo group.
Who Is Affected
- GLP-1 patients who abandon treatment. Roughly four in ten people who begin semaglutide or tirzepatide injections stop within a year, worn down by nausea and cramping. Developers now treat that dropout rate, more than potency, as the problem to solve.
- People with type 2 diabetes, who stand to gain from candidates that improved glucose control alongside weight reduction.
- Gray-market sellers, who will face pressure as approved, better-tolerated alternatives approach pharmacy shelves.
Timeline
- September 29, 2026: Petrelintide trial results published in The Lancet.
- Early October 2026: Amylin data from three developers presented at the European diabetes congress in Milan.
- By end of 2026: Expected FDA decision on CagriSema for adults with obesity or overweight without diabetes.
- Late 2026 into 2027: Expansion studies for the eloralintide-tirzepatide combination; larger petrelintide trials.
What This Means for Researchers
The Milan data shift the competitive question from how much weight a compound removes to whether patients stay on it. Amylin and GLP-1 bind to separate receptors, so pairing the two pathways adds appetite suppression without stacking identical gastrointestinal effects.
Amylin analogues such as cagrilintide already circulate on the gray market ahead of any approval. Trial percentages describe supervised clinical conditions, not unregulated vials.
How to Verify Your Peptides
- Review how peptide testing works before trusting any certificate of analysis.
- Demand HPLC and LC-MS analysis for identity and purity confirmation.
- Check identity, purity, and fill-weight standards against claimed specifications.
- See the testing FAQ for common questions about third-party lab reports.
Safe Alternatives
- Browse our research peptide directory for compounds with documented study histories.
- Check our vetted vendor listings before any purchase — sourcing matters more than price.
- Avoid sellers marketing investigational amylin combinations as ready-to-use products.
Sources
- Regulatory announcements from the U.S. Food and Drug Administration (pending CagriSema decision).
- Clinical trial publications in peer-reviewed medical journals, including The Lancet.
- Industry reports and scientific-congress presentations, 2026.